Forværret førlighed defineres som mindst 1 points øgning på EDSS - skalaen og bekræftes efter 3 måneder.
The proportion of patients with disability progression, as defined by at least one point increase in EDSS confirmed three months later, was reduced from 39% (placebo) to 30% (Rebif 22 micrograms).